B cells and tertiary lymphoid structures as determinants of tumour immune contexture and clinical outcome

WH Fridman, M Meylan, F Petitprez, CM Sun… - Nature reviews Clinical …, 2022 - nature.com
B cells are a major component of the tumour microenvironment, where they are
predominantly associated with tertiary lymphoid structures (TLS). In germinal centres within …

Cell cycle on the crossroad of tumorigenesis and cancer therapy

J Liu, Y Peng, W Wei - Trends in cell biology, 2022 - cell.com
Aberrancy in cell cycle progression is one of the fundamental mechanisms underlying
tumorigenesis, making regulators of the cell cycle machinery rational anticancer therapeutic …

Mechanisms of cancer metastasis

M Castaneda, P den Hollander, NA Kuburich… - Seminars in cancer …, 2022 - Elsevier
Metastatic cancer is almost always terminal, and more than 90% of cancer deaths result from
metastatic disease. Combating cancer metastasis and post-therapeutic recurrence …

Mechanisms of immunotherapy resistance: lessons from glioblastoma

CM Jackson, J Choi, M Lim - Nature immunology, 2019 - nature.com
Glioblastoma (GBM) is the deadliest form of brain cancer, with a median survival of less than
2 years despite surgical resection, radiation, and chemotherapy. GBM's rapid progression …

Immunogenic cell death in cancer therapy: Present and emerging inducers

J Zhou, G Wang, Y Chen, H Wang… - Journal of cellular and …, 2019 - Wiley Online Library
In the tumour microenvironment (TME), immunogenic cell death (ICD) plays a major role in
stimulating the dysfunctional antitumour immune system. Chronic exposure of damage …

Oncolytic virus immunotherapy: future prospects for oncology

J Raja, JM Ludwig, SN Gettinger, KA Schalper… - … for immunotherapy of …, 2018 - Springer
Background Immunotherapy is at the forefront of modern oncologic care. Various novel
therapies have targeted all three layers of tumor biology: tumor, niche, and immune system …

The prognostic landscape of tumor-infiltrating immune cell and immunomodulators in lung cancer

X Liu, S Wu, Y Yang, M Zhao, G Zhu, Z Hou - Biomedicine & …, 2017 - Elsevier
Tumor-infiltrating immune cells are closely associated with clinical outcome. However,
immunohistochemistry-based analysis of tumor infiltrates can be misleading as the …

Immune checkpoint inhibitors: The linchpins of modern immunotherapy

BA Wilky - Immunological reviews, 2019 - Wiley Online Library
Immune checkpoint inhibitors (ICIs) have revolutionized our approach to cancer treatment in
the past decade. While monoclonal antibodies to CTLA‐4 and PD‐1/PD‐L1 have produced …

[HTML][HTML] Pas de deux: control of anti-tumor immunity by cancer-associated inflammation

S Shalapour, M Karin - Immunity, 2019 - cell.com
In many settings, tumor-associated inflammation, supported mainly by innate immune cells,
contributes to tumor growth. Initial innate activation triggers secretion of inflammatory …

[HTML][HTML] The role of lipid metabolic reprogramming in tumor microenvironment

K Yang, X Wang, C Song, Z He, R Wang, Y Xu… - Theranostics, 2023 - ncbi.nlm.nih.gov
Metabolic reprogramming is one of the most important hallmarks of malignant tumors.
Specifically, lipid metabolic reprogramming has marked impacts on cancer progression and …